scispace - formally typeset
Open AccessJournal ArticleDOI

Bone density in patients with late onset Pompe disease

Reads0
Chats0
TLDR
It is suggested that regional BMD may moderately reduce in some patients with the late onset form of Pompe disease, although profound osteopenia was not observed and improvement of measurements in L2-L4 and femoral neck BMD z-score in some Patients with low pre-treatment values after ERT administration needs to be confirmed in larger scale studies.
Abstract
Background Pompe disease is an inherited metabolic disorder characterized by α-glycosidase deficiency, which leads to lysosomal glycogen accumulation in many different tissues. The infantile form is the most severe with a rapidly fatal outcome, while the late onset form has a greater phenotypic variability, characterized by skeletal muscle dysfunction and early respiratory involvement. Bone mineral density (BMD) has been recently reported to be reduced in many patients with both forms of the disease. Enzyme replacement therapy (ERT) is now available with an undefined, impact on BMD in patients with late onset disease.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

The emerging phenotype of late-onset Pompe disease: A systematic literature review.

TL;DR: The condition once primarily conceptualized as a limb-girdle muscle disease with prominent respiratory involvement is increasingly recognized to be a condition that results in signs and symptoms across body systems and structures.
Journal ArticleDOI

Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.

TL;DR: This study confirms LOPD clinical and genetic heterogeneity: atypical features may contribute to expand the clinical phenotype highlighting its multi-systemic nature.
Journal ArticleDOI

Neuromuscular Diseases and Bone.

TL;DR: Considering the complexity of care of patients affected by NMDs, an interdisciplinary and multimodal management strategy based on both pharmacological and non-pharmacological interventions is recommended, particularly targeting musculoskeletal issues that are closely related to functional independence as well as social implications.
References
More filters

Assessment of fracture risk and its application to screening for postmenopausal osteoporos

TL;DR: There is little evidence that osteoporosis can usefully be tackled by a public health policy to influence risk factors such as smoking, exercise and nutrition, so the selective use of screening techniques will improve the cost-benefit ratio of intervention.
Journal ArticleDOI

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.

TL;DR: The criteria required for an effective screening strategy for osteoporosis are largely met in Caucasian women as mentioned in this paper, which suggests that it is appropriate to consider targetting of treatment with agents affecting bone metabolism to susceptible individuals.
Journal ArticleDOI

An Update on the Diagnosis and Assessment of Osteoporosis with Densitometry

TL;DR: In this article, the authors consider the strengths and weaknesses of diagnostic thresholds and their use in the assessment of fracture risk, and make recommendations for actions to resolve these difficulties, including the optimal site for assessment, thresholds for men and diagnostic inaccuracies at different sites.

International osteoporosis foundation. an update on the diagnosis and assessment of osteoporosis with densitometry

J A Kanis, +1 more
TL;DR: A review considers the recent literature that has highlighted the strengths and weaknesses of diagnostic thresholds and their use in the assessment of fracture risk, and makes recommendations for actions to resolve these difficulties.
Journal Article

Consensus development conference: Prophylaxis and treatment of osteoporosis

TL;DR: A consensus development conference sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the European Foundation for Osteoporosis and Bone Disease and the American National Osteiporosis Foundation, was held in Copenhagen from 19-20 October 1990.
Related Papers (5)